现已公认辅助性化疗对经选择的原发性乳腺癌病人的疗效.尚有争论的问题是预测哪一类病人经初期“根治性”手术后容易复发,因而需行辅助性化疗.新近有些学者提出了雌激素受体值(一种乳腺癌细胞内可测定的胞浆蛋白质)对于预后之判断也具有重要意义.他们证明雌激素受体值低下的原发性乳腺癌患者,其无病间期显著缩短,以此值推测预后与其他变 The efficacy of adjuvant chemotherapy for selected primary breast cancer patients is now recognized as a controversial issue in predicting which group of patients is prone to relapse after initial “radical” surgery and therefore requires adjuvant chemotherapy. Scholars have suggested that the estrogen receptor value (a measurable cytoplasmic protein in breast cancer cells) is also important for the prognosis. They proved that the primary breast cancer patients with low estrogen receptor values ​​are disease-free. Significantly shorter intervals, the use of this value to predict the prognosis and other changes